Company intelligence / Profile preview

Ucyclyd Pharma, Inc.

Scottsdale, Arizona, USAucyclyd.com ↗

Ownership: Private
Development stage: Commercial

Overview

Ucyclyd Pharma developed and commercialized therapies for rare metabolic diseases, notably BUPHENYL® (sodium phenylbutyrate) for urea cycle disorders. The company’s assets—including rights to BUPHENYL—were acquired by Hyperion Therapeutics. Its investigational product Ravicti™ (glycerol phenylbutyrate) was also developed in collaboration with Hyperion for orphan indications including urea cycle disorders and hepatic encephalopathy. Clinical studies demonstrated non-inferiority of Ravicti compared to standard therapy in controlling blood ammonia levels in adults with UCD[4].

Therapeutic areas: Metabolic DisordersGastroenterology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

sodium phenylbutyrate

Commercial

Indications: carbamoyl-phosphate synthetase 1 deficiency (CPS1D), ornithine transcarbamylase deficiency (OTCD), argininosuccinate synthetase deficiency / citrullinemia type I (ASS deficiency)

2 more assets in the full pipeline.

Request access →

Partnerships

Hyperion TherapeuticsAmgen

Beyond the preview

Go deeper on Ucyclyd Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ucyclyd Pharma, Inc..

Explore the full profile